Satya Ganti, Ph.D.
Board, Portfolios
Satya Ganti, Ph.D., is a member of the Board overseeing Portfolios at 215 Capital, where she leverages her extensive pharmaceutical industry experience to guide and manage portfolio companies.
Dr. Ganti has over 20 years of industry experience in the pharmaceutical sector and has led analytical research and development efforts for various pharmaceutical companies, from startups to established firms. Currently, she also serves as the Head of Analytical Research & Development at WES Pharma Inc, a dynamic specialty pharmaceutical company based in Westminster, Maryland. In this role, she leads the development of analytical methods for the company's products, contributing to WES Pharma's focus on developing and manufacturing technology-driven specialty generics for the U.S. market.
Prior to her current roles, Dr. Ganti was a Senior Research Chemist at URL Pharma, Inc., where she honed her expertise in pharmaceutical research and development. Her experience spans various crucial areas in the pharmaceutical industry, including regulatory submissions, quality systems, analytical methods development, and FDA regulations.
Dr. Ganti earned her Ph.D. in Analytical Chemistry from Temple University.
